Genital Herpes - Clinical Study Recommends Gene-Eden-VIR/Novirin as a Natural Alternative to Leading Drugs for both Severe and Mild Cases: CBCD Reports Publication of a new Scientific Paper

VALLEY COTTAGE, N.Y., Oct. 25, 2016 /PRNewswire/ -- The Center for the Biology of Chronic Disease (CBCD) announces the publication of a new clinical study.  The study showed that Gene-Eden-VIR/Novirin safely and effectively decreased the duration of genital herpes outbreaks.  Acyclovir, valacyclovir, and famciclovir are the three leading drugs for genital herpes.  These drugs have side effects.  Therefore, doctors usually recommend suppressive, or long term use of these drugs in only severe cases.  In contrast, long term use of Gene-Eden-VIR/Novirin had no side effects.  As a result, the study recommends "suppressive (or long term) treatment with Gene-Eden-VIR/Novirin as a natural alternative to both suppressive (long term) and episodic (short term) treatments with current drugs, in both severe and mild genital herpes cases."  The paper was published in the important peer-reviewed medical journal Clinical and Translational Medicine (1).

Photo - http://photos.prnewswire.com/prnh/20161024/431698  
Photo - http://photos.prnewswire.com/prnh/20161024/431699

The paper is indexed on Pubmed.com, at: https://www.ncbi.nlm.nih.gov/pubmed/27766602.  Pubmed is a free search engine that lists abstracts in biomedicine and life sciences.  Pubmed is maintained by the United States National Library of Medicine (NLM), at the National Institutes of Health (NIH). 

A previous study compared Gene-Eden-VIR/Novirin with acyclovir, valacyclovir, and famciclovir, the three drugs that are widely used by doctors as the first-line treatment in genital herpes.  Surprisingly, the study showed that the natural antiviral Gene-Eden-VIR/Novirin is more effective and safer than these drugs.  This paper was published in the highly respected medical journal Drug Design, Development and Therapy (2).  This paper is also indexed on Pubmed.com, at: http://www.ncbi.nlm.nih.gov/pubmed/27621592.  A video, which presents Dr. Hanan Polansky and Dr. Edan Itzkovitz discussing their study, is available at https://youtu.be/kJzAYDEEJt0.

According to Dr. Hanan Polansky, the lead author of both studies, "To the best of our knowledge, these two studies are a major turning point for dietary supplements.  They show, for the first time, that a dietary supplement can be more effective than the leading drugs in an important drug category."

Gene-Eden-VIR/Novirin consists of five natural ingredients, quercetin, green tea extract, cinnamon extract, licorice extract, and selenium.  The Gene-Eden-VIR/Novirin formula is patent protected.  The formula was developed to target latent viruses.  Gene-Eden-VIR/Novirin was introduced in the marketplace at the end of 2009.  A previous clinical study showed that Gene-Eden-VIR/Novirin has antiviral properties.  This study was published in the medical journal Pharmacology and Pharmacy (3).

The scientists, who created the Gene-Eden-VIR/Novirin formula, used a unique scientific tool, a proprietary psycholinguistic-based, data-mining program called Computer Intuition.  The program analyzes the text found in scientific papers and highlight the most promising ideas.  The scientists' objective was to identify the natural ingredients with the most promising antiviral effects.  To achieve the objective, they analyzes more than 50,000 papers with Computer Intuition.  The results assisted them in creating the Gene-Eden-VIR/Novirin formula (3).

In summary, the new paper reports the results of a clinical study that tested the effect of long term treatment with Gene-Eden-VIR/Novirin on genital herpes outbreaks, in both severe and mild cases.  The study showed that such treatment is safe and effective, and therefore, should be recommended by healthcare professionals.

(1)    Polansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40.
(2)    Polansky, H. Javaherian, A. Itzkovitz E. Clinical study in genital herpes: natural Gene-Eden-VIR/Novirin versus acyclovir, valacyclovir, and Famciclovir. Drug Design, Development and Therapy 2016:10 2713-2722
(3)    Polansky H, Itzkovitz E. Gene-Eden-VIR is antiviral: results of a post marketing clinical study. Pharmacol Pharm. 2013;4(6A):1-8

Media contact:
Mike Davis
[email protected] 
585-250-9999

SOURCE The Center for the Biology of Chronic Disease